AGT and cardiac hypertrophy: Similarly, a new PARP-1 inhibitor, AG-690/11026014 (6014), has been revealed to retard AngII-induced cardiac hypertrophy, partly because of the activation of Sirt6 by elevating intracellular NAD + levels (Liu et al., 2014).